---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-050055"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:17:35.715700+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics enters new employment agreements with CEO and CFO effective June 4, 2025

## Summary
- CEO Chris Ehrlich receives base salary of $480,000/year and a one-time performance bonus of 50% of base salary.
- CFO Andrew Kucharchuk receives base salary of $300,000/year and a one-time performance bonus of 30% of base salary.
- Ehrlich receives equity awards including an option for 238,971 shares (granted March 4, 2025) and a second option for 185,529 shares.
- Kucharchuk receives an option for 152,500 shares, subject to board approval, vesting over time and performance milestones.
- The new agreements replace prior consulting agreements and convert both roles to full-time employment.

## SEC filing metadata
- accession: 0001213900-25-050055
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/ea0244195-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-050055
- JSON: https://secwatch.observer/filing/0001213900-25-050055.json
- Plain text: https://secwatch.observer/filing/0001213900-25-050055.txt

## Key facts
- Executive change
  Chris Ehrlich was appointed as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Company agreed to employ Mr. Ehrlich as the Company’s Chief Executive Officer as of and from June 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm
- Executive change
  Andrew Albert Kucharchuk was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the Company agreed to employ Mr. Kucharchuk as the Company’s Chief Financial Officer as of and from June 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.